Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: Interim analysis from an open-label extension study

Journal of the American Academy of Dermatology

Volumn 61, Issue 3, 2009, Pages 421-425

  Monheit, Gary D ^a,b   Cohen, Joel L ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b TOTAL   (France)

^c AboutSkin Dermatology   (United States)

Author keywords

botulinum toxin type A

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; EVALUATION RESEARCH; FEMALE; HUMAN; INCIDENCE; INJECTION SITE; LONG TERM CARE; MALE; PRIORITY JOURNAL; PTOSIS; RISK ASSESSMENT; WRINKLE;

ADULT; AGED; ANTIBODIES; BOTULINUM TOXIN TYPE A; CHEMISTRY, PHARMACEUTICAL; FEMALE; FOLLOW-UP STUDIES; HORNER SYNDROME; HUMANS; INCIDENCE; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; NEUROTOXINS; SKIN AGING;

EID: 68849099067     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.03.049     Document Type: Article

References (15)

1. FDA approves Dysport for therapeutic and aesthetic uses [press release] (April 30, 2009), Medicis Aesthetics, Inc, Scottsdale, AZ
2. Ascher B., Klap P., Marion M.H., and Chanteloub F. Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles: an initial study. Ann Chir Plast Esthet 40 (1995) 67-76
3. Ascher B. Facial rejuvenation by non-endoscopic lifting and botulinum toxin injection. Cahiers Ophthalmol 45 (2000) 25-31
4. Olver J.M. Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease. BMJ 82 (1998) 528-533
5. Erian A., and Ionescu N.E. Combination treatment of glabellar rhytids. Int J Cosmet Surg 7 (1999) 14-17
6. Feller G., Bayerl C., Jung E., and Rzany B. Treatment of dynamic facial wrinkles with botulinum toxin type A (Dysport)-a pilot study. Akt Dermatol 26 (2000) 65-69
7. Le Louarn C. Botulinum toxin and facial wrinkles: a new injection procedure. Ann Chir Plast Esthet 5 (1998) 526-533
8. Lowe N.J. Botulinum toxin type A for facial rejuvenation: United States and United Kingdom perspectives. Dermatol Surg 24 (1998) 1216-1225
9. Monheit G., Carruthers A., Brandt F., and Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33 (2007) S51-S59
10. Lowe P., Patnaik R., and Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 55 (2006) 975-980
11. Asher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., and Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51 (2004) 223-233
12. Honeck P., Weiss C., Sterry W., and Rzany B. Gladys Study Group. Reproducibility of a four-point clinical severity score for glabellar frown lines. Br J Dermatol 149 (2003) 306-310
13. Rzany B., Dill-Muller D., Grablowitz D., Heckman M., and Caird D. German-Austrian Retrospective Study Group. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 subjects. Dermatol Surg 33 (2007) S18-S25
14. Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., Niforos F., et al. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surg J 25 (2005) 365-375
15. Carruthers J., Lowe N., Menter M., Gibson J., Norquist M., Mordaunt J., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46 (2002) 840-849